DELFIA检测血清PSA、fPSA及fPSA/PSA在前列腺疾病诊断中的应用

目的：探讨双标记时间分辨荧光免疫分析(DELFIA)检测血清PSA、fPSA及fPSA/PSA在前列腺疾病诊断中的应用。方法：应用DELFIA法检测正常对照组(34例)、前列腺炎组(46例)、前列腺增生症组(123例)及前列腺癌组(39例)血清PSA、fPSA含量及fPSA/PSA。结果：前列腺癌组PSA、fPSA与其他三组比较差异均有显著性(P＜0.01)，而其他3组之间比较差异显著性(P＞0.05)；前列腺癌组fPSA/PSA明显降低，与其他3组比较差异均有显著性(P＜0.05)。结论：应用DELFIA检测PSA、fPSA含量及fPSA/PSA是提高前列腺疾病诊断与鉴别诊断更为有效的方法，尤其对前列腺癌诊断更有意义。

Application of serum PSA, fPSA detections and fPSA/PSA evaluation for diagnosis and therapy of prostatic diseases with DELFIA technique

Objective To investigate the application of PSA, fPSA concentrations and fPSA/PSA value for diagnosis and therapy of prostatic diseases detected with dissociation enhanced lauthanide fluoroimmunoassay (DELFIA) technique . Methods Thirty-four cases of normal individuals were used as control group, 46 patients with prostatitis as prostatitis group, 123 patients with prostatic hyperplasia as BPH group and 39 patients with prostate cancer as prostate cancer group. PSA, fPSA concentrations and fPSA/PSA value were detected with DELFIA technique. Results In prostate cancer group, the PSA and fPSA concentrations were significantly higher than those in other 3 groups (P<0.01),as fPSA/PSA value was remarkably lower than those in the other 3 groups (P<0.05).However, the fPSA/PSA values in other 3 groups demonstrated no significant difference (P>0.05). Conclusion DELFI A technique is an effective method to improve the diagnosis and differential diagnosis of prostatic diseases, especially for prostate cancer.